BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/23/2026 8:57:28 AM | Browse: 3 | Download: 13
 |
Received |
|
2026-06-15 08:34 |
|
Peer-Review Started |
|
2026-06-15 08:34 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2026-07-24 06:38 |
|
Revised |
|
2026-08-05 23:57 |
|
Publication Fee Transferred |
|
2026-09-01 09:14 |
|
Second Decision by Editor |
|
2026-09-22 03:46 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-09-22 09:54 |
|
Articles in Press |
|
2026-09-22 09:54 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-09-23 02:21 |
|
Publish the Manuscript Online |
|
2026-09-23 08:57 |
| ISSN |
2218-4333 (online) |
| Open Access |
Open-Access: This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Observational Study |
| Article Title |
Efficacy of two programmed cell death 1 combination regimens in recurrent and/or metastatic head and neck carcinoma: A real-world retrospective study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jia-Xin Wang, Tian-Xiao Wang, Yun-Tao Song, Guo-Hui Xu, Ya-Bing Zhang and Bin Zhang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Bin Zhang, Department of Head and Neck Surgery, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China. docbinzhang@hotmail.com |
| Key Words |
Head and neck squamous cell carcinoma; Programmed cell death 1 inhibitor; Cetuximab; Anlotinib; Immuno-targeted therapy |
| Core Tip |
Programmed cell death 1 (PD-1) inhibitors combined with cetuximab or anlotinib exhibit distinct therapeutic profiles in recurrent and/or metastatic head and neck squamous cell carcinoma. In this real-world cohort study, PD-1 inhibitor plus cetuximab was associated with significantly prolonged overall survival, whereas PD-1 inhibitor plus anlotinib showed favorable tumor response and disease control. These distinct efficacy profiles may help inform individualized treatment selection for PD-1-based immunotherapy-targeted therapy combinations. |
| Publish Date |
2026-09-23 08:57 |
| Citation |
Wang JX, Wang TX, Song YT, Xu GH, Zhang YB, Zhang B. Efficacy of two programmed cell death 1 combination regimens in recurrent and/or metastatic head and neck carcinoma: A real-world retrospective study. World J Clin Oncol 2026; 17(9): 124416
|
| URL |
https://www.wjgnet.com/2218-4333/full/v17/i9/124416.htm |
| DOI |
https://doi.org/10.5306/wjco.124416 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
